Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Why do genetics research?
- Genetically driven drug targets
- Defining genetic determinants of disease
- EXCEED Study
- Genome-wide association study (GWAS)
- Phenome-wide association study (PheWAS)
- Chronic respiratory disease
- Measuring lung function
- SpiroMeta consortium
- Recent study approaches and findings
- Multi-ancestry lung function GWAS
- Ancestries included in the meta-analysis
- Study outline
- Discovery: association testing
- Identification of putative causal genes
- Genes show implicated mechanisms
- Putative causal genes: examples
- Pathway analysis
- Genetic risk scores and polygenic scores
- Polygenic risk scores
- PheWAS: FEV1/FVC Genetic Risk Score (GRS)
- PheWAS: FVC GRS
- PheWAS: elastic fibre formation pathway-specific GRS
- PheWAS: PI3K-Akt signalling pathway-specific GRS
- Future directions
- Future work and funding
- Acknowledgements
Topics Covered
- Routine use of genetic evidence in drug target discovery and validation
- Genetically supported targets can double the success rate in clinical development
- COPD has the highest prevalence of chronic respiratory diseases globally
- SpiroMeta consortium: understanding the genetic determinants of COPD
- Understanding the tractability of drug targets
- Identification of statistically independent genetic associations (signals) for lung function
- Use of phonome-wide association studies
- DeepPheWAS: testing pathway-specific GRS to infer possible consequences of intervening in pathways underlying lung function
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Tobin, M. (2023, July 31). Genetics of chronic obstructive pulmonary disease (COPD) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/GFQO8310.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Martin Tobin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
I'm Martin Tobin.
I'm Professor of Genetic
Epidemiology and
Public Health at the
University of Leicester and
I'll be talking about
the genetics of
Chronic Obstructive
Pulmonary Disease or COPD.
So before we start, I'll just
outline what I'll
cover in this talk.
I'll first introduce why we
undertake genetics research,
what it can tell us.
I'll then move on
to how we generate
evidence about
genetic determinants
of pulmonary diseases.
I'll give some
specific examples of
recent studies relating to
genomics as lung function and
COPD and then I'll move on to
discussion as to potential
future directions.
0:52
So let's begin by describing
why we undertake
genetic research.
In general, we're
interested in studying
genetic associations
with disease or with
disease related traits, related
to susceptibility or
progression of disease for
example in order to
have evidence that
we can have confidence in
about disease mechanisms,
and that evidence in turn can
often be used in addition for
prediction to help us make
decisions about
future diagnostics,
potential new therapeutics
or therapeutics that
can be retargeted or
repurposed from other areas,
as well as evidence
about how to target
those treatments and
how to prevent disease.
So what is it about
genetic evidence that's
special in some way?
Well the issue is that
certainly in observational
epidemiology,
many associations
that we observe
be they between non-genetic
risk factors or
biomarker levels and disease are
often confounded and subject
to reverse causation.
Whereas genetic variants
are allocated by
an essentially random process
during gamete formation
and this means
that genetic
associations provide
particularly strong
evidence that we can have
additional confidence
in when we're actually
making important decisions
about what to prioritize,
for example for
drug development.
In fact, Nelson and colleagues
have shown that using
genetic evidence to support
drug targets actually
doubles the success rate
during drug development.
Whilst many of these goals of
genetics research do seem rather
grand and have come in for
some criticism that maybe
there is a degree
of hype there ,
we are now actually seeing
practical examples
coming through.
So on the next slide you
will see some examples